Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
經治療的2型糖尿病成人中,Empagliflozin與Dapagliflozin的心血管效果比較:一項目標試驗模擬。
Circulation 2024-08-29
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
二型糖尿病患者中,無心血管或腎臟疾病病史的患者,達帕格列酮和恩帕格列酮在心血管和腎臟結果之比較。
PLoS One 2022-12-07
Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.
二型糖尿病患者達帕格列酮和恩帕格列酮臨床結果的比較評估。
Ir J Med Sci 2023-09-28
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Empagliflozin在歐洲和亞洲地區的EMPRISE研究結果顯示,與二肽基肽酶-4抑制劑相比,與心血管疾病有關和無關的成年人相比,心血管風險較低。
Cardiovasc Diabetol 2023-11-21
Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes.
非糖尿病患者中 empagliflozin 和 dapagliflozin 對心血管結果的影響。
Am J Cardiol 2024-04-19
Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus.
糖尿病患者中達帕格列酮與恩帕格列酮的心血管結果比較。
Clin Cardiol 2024-03-14
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes.
二型糖尿病患者中 Empagliflozin 與二肽基肽酶-4 抑制劑的腎臟和心血管效果比較。
Am J Cardiol 2024-04-19
Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure.
Empagliflozin與Dapagliflozin在心臟衰竭患者中的比較結果。
JAMA Netw Open 2024-05-02
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety.
心衰竭與2型糖尿病中的Dapagliflozin:療效、心臟及腎臟效果、安全性。
World J Diabetes 2024-08-05